Pseudovitelliform maculopathy associated with deferoxamine toxicity: multimodal imaging and electrophysiology of a rare entity
Author(s) -
Kelly M. Bui,
Srinivas R. Sadda,
Hani Salehi-Had
Publication year - 2017
Publication title -
digital journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.223
H-Index - 7
ISSN - 1542-8958
DOI - 10.5693/djo.02.2016.12.001
Subject(s) - deferasirox , deferoxamine , medicine , toxicity , discontinuation , maculopathy , lesion , pathology , surgery , thalassemia , retinopathy , endocrinology , diabetes mellitus
Deferoxamine is a commonly used chelating agent for secondary hemochromatosis. We report a rare retinal manifestation of deferoxamine toxicity in a 68-year-old man and provide supporting multimodal imaging and electrophysiology. The patient had iron overload related to transfusion-dependent myelodysplastic syndrome and developed a pseudovitelliform macular lesion related to deferoxamine toxicity. We also describe for the first time the worsening of this maculopathy on deferasirox, an alternative chelating agent. Macular pseudovitelliform lesion is a unique manifestation of deferoxamine toxicity that can be mistaken for pattern dystrophy. It is important to recognize this manifestation, because discontinuation of the offending agent may halt or reverse the toxicity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom